Qure expectations today and tomorrow

**Bottom Line 🩺 → QURE’s 67%+ plunge this afternoon was driven by a surprise FDA setback on its Huntington’s gene-therapy program (AMT-130). With the stock now crushed below every major support level, the near-term outlook (next 24-48 hrs) is one of extreme volatility and a bias toward continued weakness unless management can quickly restore confidence.** --- ### What just happened? | Event | Details | Market Impact | |-------|---------|---------------| | FDA reverses stance on AMT-130 data | Agency now says Phase I/II external-control study is *not* sufficient for a Biologics License Application | Sparked a ~67-75% single-day price collapse to ~$32, shattering the prior “wide” support zone at $53-58 | ### Where does that leave the chart? 1. **Price levels** • Pre-crash supports ($53.6–58.0) and resistances ($66.9–71.3) from last week’s quantitative model are now obsolete; the stock sits 40% below the former floor. 2. **Technical context (post-crash)** • The gap down to $32.46 (today’s close) creates an “air pocket” up to the mid-50s. Gaps of this size in biotech tend to act as **resistance** on any reflex rally. • No nearby historical support until the $28–30 zone (Nov-Dec 2024 consolidation). 3. **Volume & volatility** • Intraday volume ran >10× average (per market data in news reports), suggesting capitulation but also setting the stage for sharp whipsaws. ### Short-term expectation (Today → Tomorrow) • **Base case:** Follow-through selling overnight and into tomorrow’s open as funds de-risk and margin calls hit. • **Alternate scenario:** A “dead-cat” bounce of 10-20% is possible if shorts cover and bargain hunters probe the gap—but sellers likely re-emerge near $40–45. • **Catalysts:** – Any company/FDA update or analyst downgrade could accelerate moves. – Options expiry later this week may amplify swings. ### How to navigate from here 1. **If you’re already long:** – Re-evaluate your thesis: the core value driver (AMT-130) now faces an uncertain timeline. – Consider whether to trim, hedge with puts, or exit to protect capital; the model’s prior “Sell” signal still stands . 2. **If you’re on the sidelines:** – Patience is key—wait for clarity from FDA meeting minutes (due within 30 days) and management guidance. – Use the $28–30 area as a potential line-in-the-sand for valuation support; any sustained move back above $50 would require concrete positive data or partnership news. 3. **Volatility strategies:** – Implied volatility has likely spiked; selling out-of-the-money calls/puts could monetize premium, but be mindful of event risk. – Keep position sizes small—biotech regulatory paths can shift rapidly. --- 🤔 **Your move:** Given today’s shock drop and the uncertain regulatory path, how comfortable are you with holding—or initiating—positions that can swing 30-50% on a headline? Knowing your short-term risk tolerance will help tailor a risk-managed game plan.